JAZZ · Jazz Pharmaceuticals plc
United States · RS rating 50 · As of 2026-10-14
| Price | 209.65 USD |
|---|---|
| 1-day change | -0.3% |
| RS rating (overall / 1M / 3M / 12M) | 50 / 18 / 27 / 90 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 36 / 48 / 22 |
| Industry group (rank) | Medical-Ethical Drugs (91) |
| EPS growth Q/Q | -21.3% |
| Sales growth Q/Q | +6.4% |
| Distance from 52-week high | +19.9% |
| Market cap (USD) | $12.3B |